Interrelationships among platelet-activating factor and lipoprotein-associated phospholipase A
Lp-PLA2
PAF
cardiovascular disease
inflammation
lipoprotein-associated phospholipase A2
platelet-activating factor
risk factors
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
10
11
2022
accepted:
01
12
2022
medline:
14
4
2023
pubmed:
21
12
2022
entrez:
20
12
2022
Statut:
ppublish
Résumé
Traditionally cardiovascular disease (CVD) risk has been assessed through blood lipids and inflammatory marker C-reactive protein (hsCRP). Recent clinical interest in novel pro-inflammatory markers platelet-activating factor (PAF) and lipoprotein-associated phospholipase A
Substances chimiques
1-Alkyl-2-acetylglycerophosphocholine Esterase
EC 3.1.1.47
C-Reactive Protein
9007-41-4
Platelet Activating Factor
0
Cholesterol, HDL
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
457-471Subventions
Organisme : Australian Government Research Training Program Scholarship
Informations de copyright
© 2022 The Authors. BioFactors published by Wiley Periodicals LLC on behalf of International Union of Biochemistry and Molecular Biology.
Références
Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor-a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003;105:705-16.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. Circulation. 2003;107:499-511.
Castro AR, Silva SO, Soares SC. The use of high sensitivity C-reactive protein in cardiovascular disease detection. J Pharm Pharm Sci. 2018;21:496-503.
Haybar H, Shokuhian M, Bagheri M, Davari N, Saki N. Involvement of circulating inflammatory factors in prognosis and risk of cardiovascular disease. J Mol Cell Cardiol. 2019;132:110-9.
Fu Y, Wu Y, Liu E. C-reactive protein and cardiovascular disease: from animal studies to the clinic (review). Exp Ther Med. 2020;20:1211-9.
Thiele JR, Habersberger J, Braig D, Schmidt Y, Goerendt K, Maurer V, et al. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation. Circulation. 2014;130:35-50.
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-40.
Bower JK, Lazo M, Juraschek SP, Selvin E. Within-person variability in high-sensitivity C-reactive protein. Arch Intern Med. 2012;172:1519-21.
English CJ, Mayr HL, Lohning AE, Reidlinger DP. The association between dietary patterns and the novel inflammatory markers platelet-activating factor and lipoprotein-associated phospholipase A2: a systematic review. Nutr Rev. 2022;80:1371-91.
Triggiani M, Schleimer RP, Warner JA, Chilton FH. Differential synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells. J Immunol. 1991;147:660-6.
Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest. 1995;95:2297-303.
Lacasse C, Turcotte S, Gingras D, Stankova J, Rola-Pleszczynski M. Platelet-activating factor stimulates Interleukin-6 production by human endothelial cells and synergizes with tumor necrosis factor for enhanced production of granulocyte-macrophage colony stimulating factor. Inflammation. 1997;21:145-58.
Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem. 2000;69:419-45.
Tsoupras A, Lordan R, Zabetakis I. Inflammation, not cholesterol, is a cause of chronic disease. Nutrients. 2018;10:604.
Lordan R, Tsoupras A, Zabetakis I, Demopoulos CA. Forty years since the structural elucidation of platelet-activating factor (PAF): historical, current, and future research perspectives. Molecules. 2019;24:4414.
Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Inflammation as an early component of atherosclerosis and vascular damage. Jpn Circ J. 1996;60:137-41.
Handley DA, Arbeeny CM, Lee ML, Van Valen RG, Saunders RN. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology. 1984;8:137-42.
Rouis M, Nigon F, John Chapman M. Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages. Biochem Biophys Res Commun. 1988;156:1293-301.
Dentan C, Lesnik P, Chapman MJ, Ninio E. Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the inflammatory reaction in atherogenesis. Eur J Biochem. 1996;236:48-55.
Gaut JP, Heinecke JW. Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med. 2001;11:103-12.
Sukriti S, Tauseef M, Yazbeck P, Mehta D. Mechanisms regulating endothelial permeability. Pulm Circ. 2014;4:535-51.
Satoh K, Imaizumi T, Yoshida H, Hiramoto M, Takamatsu S. Increased levels of blood platelet-activating factor (PAF) and PAF-like lipids in patients with ischemic stroke. Acta Neurol Scand. 1992;85:122-7.
Chen H, Zheng P, Zhu H, Zhu J, Zhao L, El Mokhtari NE, et al. Platelet-activating factor levels of serum and gingival crevicular fluid in nonsmoking patients with periodontitis and/or coronary heart disease. Clin Oral Investig. 2010;14:629-36.
Zheng G-H, Xiong S-Q, Mei L-J, Chen H-Y, Wang T, Chu J-F. Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case control study. Inflammation. 2012;35:1419-28.
Detopoulou P, Fragopoulou E, Nomikos T, Antonopoulou S, Kotroyiannis I, Vassiliadou C, et al. Baseline and 6-week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers-a pilot study. Angiology. 2013;64:522-8.
Kudolo GB, DeFronzo RA. Urinary platelet-activating factor excretion is elevated in non-insulin dependent diabetes mellitus. Prostaglandins Other Lipid Mediat. 1999;57:87-98.
Cavallo-Perin P, Lupia E, Gruden G, Olivetti C, De Martino A, Cassader M, et al. Increased blood levels of platelet-activating factor in insulin-dependent diabetic patients with microalbuminuria. Nephrol Dial Transplant. 2000;15:994-9.
Yin H, Shi A, Wu J. Platelet-activating factor promotes the development of non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2022;15:2003-30.
Derewenda ZS, Derewenda U. The structure and function of platelet-activating factor acetylhydrolases. Cell Mol Life Sci. 1998;54:446-55.
Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res. 2009;50(Suppl):S237-42.
Dennis EA. Allosteric regulation by membranes and hydrophobic subsites in phospholipase A(2) enzymes determine their substrate specificity. J Biol Chem. 2022;298:101873.
Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57-68.
Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2094-9.
Tellis CC, Tselepis AD. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase a₂ (Lp-PLA₂) bound to LDL and HDL. Curr Pharm Des. 2014;20:6256-69.
Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791:327-38.
Silva IT, Mello APQ, Damasceno NRT. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review. Lipids Health Dis. 2011;10:170.
Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25:923-31.
Kohno M, Yokokawa K, Yasunari K, Minami M, Kano H, Hanehira T, et al. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation. 1998;98:353-9.
Shi Y, Zhang P, Zhang L, Osman H, Mohler ER, Macphee C, et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 2007;191:54-62.
Steen DL, O'Donoghue ML. Lp-PLA2 inhibitors for the reduction of cardiovascular events. Cardiol Ther. 2013;2:125-34.
Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: the story continues. Med Res Rev. 2020;40:79-134.
Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008;101:41f-50f.
Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A 2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159-65.
Chung H, Kwon HM, Kim J-Y, Yoon Y-W, Rhee J, Choi E-Y, et al. Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome. Yonsei Med J. 2014;55:1507-15.
Hu G, Liu D, Tong H, Huang W, Hu Y, Huang Y. Lipoprotein-associated phospholipase A2 activity and mass as independent risk factor of stroke: a meta-analysis. Biomed Res Int. 2019;2019:1-11.
Perrot N, Thériault S, Rigade S, Chen HY, Dina C, Martinsson A, et al. Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans. Heart. 2020;106:1407-12.
Topbas C, Swick A, Razavi M, Anderson NL, Pearson TW, Bystrom C. Measurement of lipoprotein-associated phospholipase A2 by use of 3 different methods: exploration of discordance between ELISA and Activity assays. Clin Chem. 2018;64:697-704.
De Stefano A, Mannucci L, Tamburi F, Cardillo C, Schinzari F, Rovella V, et al. Lp-PLA(2), a new biomarker of vascular disorders in metabolic diseases. Int J Immunopathol Pharmacol. 2019;33:2058738419827154.
Pantazi D, Tellis C, Tselepis AD. “SI: PAF” oxidized phospholipids and lipoprotein-associated phospholipase A2 (Lp-PLA2) in atherosclerotic cardiovascular disease: an update. BioFactors. 2022;48(6):1257-1270.
Wang D, Guo X, Hou L, Cheng X, You T, Li H, et al. Measuring lipoprotein-associated phospholipase A2 activity in China: protocol comparison and recalibration. J Clin Lab Anal. 2019;33:e22628.
Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis. 2008;199:110-5.
Enkhmaa B, Anuurad E, Zhang W, Pearson TA, Berglund L. Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population. Atherosclerosis. 2010;211:526-30.
Lee KK, Fortmann SP, Varady A, Fair JM, Go AS, Quertermous T, et al. Racial variation in lipoprotein-associated phospholipase A 2 in older adults. BMC Cardiovasc Disord. 2011;11:38.
Gregson JM, Freitag DF, Surendran P, Stitziel NO, Chowdhury R, Burgess S, et al. Genetic invalidation of Lp-PLA(2) as a therapeutic target: large-scale study of five functional Lp-PLA(2)-lowering alleles. Eur J Prev Cardiol. 2017;24:492-504.
Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148-55.
Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570-5.
Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411-6.
Yokote K, Suzuki A, Li Y, Matsuoka N, Teramoto T. Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects. Int J Clin Pharmacol Ther. 2019;57:575-89.
Gajos G, Zalewski J, Mostowik M, Konduracka E, Nessler J, Undas A. Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina. Nutr Metab Cardiovasc Dis. 2014;24:434-9.
Stojanovic M, Radenkovic M. Omega-3 fatty acids are capable to decrease the lipoprotein-associated phospholipase A2 blood level. Atherosclerosis. 2018;275:e237.
Palur Ramakrishnan AV, Varghese TP, Vanapalli S, Nair NK, Mingate MD. Platelet activating factor: a potential biomarker in acute coronary syndrome? Cardiovasc Ther. 2017;35:64-70.
Li J, Cao T, Wei Y, Zhang N, Zhou Z, Wang Z, et al. A review of novel cardiac biomarkers in acute or chronic cardiovascular diseases: the role of soluble ST2 (sST2), lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), and procalcitonin (PCT). Dis Markers. 2021;2021:6258865.
Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. New Jersey: Lawrence Erlbaum Associates; 1988.
Brown RE, Randhawa AK, Canning KL, Fung M, Jiandani D, Wharton S, et al. Waist circumference at five common measurement sites in normal weight and overweight adults: which site is most optimal? Clin Obes. 2018;8:21-9.
O'Brien E, Coats A, Owens P, Petrie J, Padfield PL, Littler WA, et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society. BMJ. 2000;320:1128-34.
Armstrong T, Bull F. Development of the World Health Organization Global Physical Activity Questionnaire (GPAQ). J Public Health. 2006;14:66-70.
National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk; 2012.
Detopoulou P, Nomikos T, Fragopoulou E, Stamatakis G, Panagiotakos DB, Antonopoulou S. PAF and its metabolic enzymes in healthy volunteers: interrelations and correlations with basic characteristics. Prostaglandins Other Lipid Mediat. 2012;97:43-9.
Australian Government Department of Health and Aged Care. COVID-19 Vaccination - Geographic vaccination rates - LGA; 2022. Available from: www.health.gov.au/resources/collections/covid-19-vaccination-geographic-vaccination-rates-lga.
Ostrowski SR, Søgaard OS, Tolstrup M, Staerke NB, Lundgren J, Østergaard L, et al. Inflammation and platelet activation after COVID-19 vaccines-possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis. Front Immunol. 2021;12:779453.
Antonopoulou S, Petsini F, Detopoulou M, Theoharides TC, Demopoulos CA. Is there an interplay between the SARS-CoV-2 spike protein and platelet-activating factor? Biofactors. 2022;1-13.
Yan B, Chu H, Yang D, Sze K-H, Lai P-M, Yuan S, et al. Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication. Viruses. 2019;11:73.
Raheem SG. Investigating platelet-activating factor as a potent proinflammatory mediator in coronary atherosclerotic patients. Cell Mol Biol (Noisy-le-Grand). 2021;67:1-4.
Li Y, Jiang Y, Zhang Y, Li N, Yin Q, Liu L, et al. Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients. Sci Rep. 2021;11:6811.
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65.
Mirjanić-Azarić B, Derić M, Vrhovac M, Males-Bilić L. Correlation between C-reactive protein levels with leading risk factors for cardiovascular disease in men. Med Pregl. 2008;61:164-8.
Agirbasli M, Tanrikulu A, Acar Sevim B, Azizy M, Bekiroglu N. Total cholesterol-to-high-density lipoprotein cholesterol ratio predicts high-sensitivity C-reactive protein levels in Turkish children. J Clin Lipidol. 2015;9:195-200.
Arena R, Arrowood JA, Fei DY, Helm S, Kraft KA. The relationship between C-reactive protein and other cardiovascular risk factors in men and women. J Cardiopulm Rehabil. 2006;26:323-7. quiz 328-329.
Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med. 2005;15:158-61.
Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. BMJ: Br Med J. 2014;349:g4379.
Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-12.
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933-42.
Allard-Ratick M, Khambhati J, Topel M, Sandesara P, Sperling L, Quyyumi A. 50Elevated HDL-C is associated with adverse cardiovascular outcomes. Eur Heart J. 2018;39:ehy564.50.
Li H, Qian F, Zuo Y, Yuan J, Chen S, Wu S, et al. U-shaped relationship of high-density lipoprotein cholesterol and incidence of total, ischemic and hemorrhagic stroke: a prospective cohort study. Stroke. 2022;53:1624-32.
Liu C, Dhindsa D, Almuwaqqat Z, Ko Y-A, Mehta A, Alkhoder AA, et al. Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk populations. JAMA Cardiol. 2022;7:672-80.
Kosmas CE, Martinez I, Sourlas A, Bouza KV, Campos FN, Torres V, et al. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context. 2018;7:212525.
Salazar J, Olivar LC, Ramos E, Chávez-Castillo M, Rojas J, Bermúdez V. Dysfunctional high-density lipoprotein: an innovative target for proteomics and lipidomics. Cholesterol. 2015;2015:296417.
Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13:48-60.
El Khoudary SR, Chen X, Nasr AN, Billheimer J, Brooks MM, McConnell D, et al. HDL (high-density lipoprotein) subclasses, lipid content, and function trajectories across the menopause transition: SWAN-HDL study. Arterioscler Thromb Vasc Biol. 2021;41:951-61.
Detopoulou P, Nomikos T, Fragopoulou E, Panagiotakos DB, Pitsavos C, Stefanadis C, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults. Lipids Health Dis. 2009;8:19.
Ntzouvani A, Giannopoulou E, Fragopoulou E, Nomikos T, Antonopoulou S. Energy intake and plasma adiponectin as potential determinants of lipoprotein-associated phospholipase A2 activity: a cross-sectional study. Lipids. 2019;54:629-40.
Chen YH, Li WC, Chen YC, Yeh WC, Yu W, Hung HY, et al. The correlation between lipoprotein associated phospholipase a(2) and central overweight status. Int J Immunopathol Pharmacol. 2021;35:20587384211048562.
Halonen M, Palmer JD, Lohman IC, McManus LM, Pinckard RN. Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit. Am Rev Respir Dis. 1980;122:915-24.
Tanaka S, Kasuya Y, Masuda Y, Shigenobu K. Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, Guinea pigs, rabbits, and dogs. J Pharmacobiodyn. 1983;6:866-73.
Nakamura T, Murata T. Regulation of vascular permeability in anaphylaxis. Br J Pharmacol. 2018;175:2538-42.
Albert MA, Glynn RJ, Ridker PM. Effect of physical activity on serum C-reactive protein. Am J Cardiol. 2004;93:221-5.
Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45:1563-9.
Plaisance EP, Grandjean PW. Physical activity and high-sensitivity C-reactive protein. Sports Med. 2006;36:443-58.
Esteghamati A, Morteza A, Khalilzadeh O, Anvari M, Noshad S, Zandieh A, et al. Physical inactivity is correlated with levels of quantitative C-reactive protein in serum, independent of obesity: results of the national surveillance of risk factors of non-communicable diseases in Iran. J Health Popul Nutr. 2012;30:66-72.
Buyukyazi G, Ulman C, Taneli F, Esen H, Gozlukaya F, Ozcan I, et al. The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women. Sci Sports. 2010;25:245-52.
Wooten JS, Nambi P, Gillard BK, Pownall HJ, Coraza I, Scott LW, et al. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc. 2013;45:1043-50.
Rood B. Effects of a 12-week vigorous interval training intervention on proinflammatory markers in post-operative bariatric and obese participants. Masters Theses 640 2019.
Clark K, Sharp S, Womack CJ, Kurti SP, Hargens TA. Increased sedentary time and decreased physical activity increases lipoprotein associated phospholipase A(2) in obese individuals. Nutr Metab Cardiovasc Dis. 2022;32:1703-10.
Liu X, Zhou W, Fan W, Li A, Pang J, Chen Z, et al. The benefit of exercise rehabilitation guided by 6-minute walk test on lipoprotein-associated phospholipase A2 in patients with coronary heart disease undergoing percutaneous coronary intervention: a prospective randomized controlled study. BMC Cardiovasc Disord. 2022;22:177.
Cozlea DL, Farcas DM, Nagy A, Keresztesi AA, Tifrea R, Cozlea L, et al. The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. Curr Health Sci J. 2013;39:225-31.
Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837-42.
Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165:2479-84.
Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006;166:2073-80.
Feng L-M, Feng G-F, Chen Y. Evaluation of lipoprotein-associated phospholipase A2 in healthy Chinese Han adult serum. Lipids Health Dis. 2014;13:6.
Acevedo M, Varleta P, Kramer V, Valentino G, Quiroga T, Prieto C, et al. Comparison of lipoprotein-associated phospholipase A2 and high sensitive C-reactive protein as determinants of metabolic syndrome in subjects without coronary heart disease: In search of the best predictor. Int J Endocrinol. 2015;2015:934681.
Cen JM, Cheng J, Xiong QY, Mei BQ, Cai WB, Yang XL. Study on the correlation between the concentration of plasma lipoprotein-associated phospholipase A2 and coronary heart disease. Chronic Dis Transl Med. 2015;1:105-9.
Detopoulou P, Karantonis HC, Antonopoulou S. Mediterranean diet and its protective mechanisms against cardiovascular disease: an insight into platelet activating factor (PAF) and diet interplay. Ann Nutr Disord Ther. 2015;2:1016.
Vigo C. Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. J Biol Chem. 1985;260:3418-22.
Sato A, Oe K, Yamanaka H, Yokoyama I, Ebina K. C-reactive protein specifically enhances platelet-activating factor-induced inflammatory activity in vivo. Eur J Pharmacol. 2014;745:46-51.
Queensland Government. Queensland Government.